# EDGAR Filing Document

**Accession Number:** 0002079364
**File Stem:** 0001829126-26-001328
**Filing Date:** 2026-2
**Character Count:** 4213
**Document Hash:** 779a674831362f61b574cfe281073f8f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-001328.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001829126-26-001328

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veraxa Biotech Holding AG
- **CENTRAL INDEX KEY:** 0002079109
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TALACKER 35
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **ZIP:** 8001
- **BUSINESS PHONE:** 41443858450

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TALACKER 35
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **ZIP:** 8001
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veraxa Biotech AG
- **CENTRAL INDEX KEY:** 0002079364
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TALACKER 35
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **ZIP:** 8001
- **BUSINESS PHONE:** 41443858450

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TALACKER 35
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **ZIP:** 8001
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Voyager Acquisition Corp./Cayman Islands
- **CENTRAL INDEX KEY:** 0002006815
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** C/O WINSTON & STRAWN LLP
- **STREET 2:** 800 CAPITOL ST., STE 2400
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77002
- **BUSINESS PHONE:** 03477204333

**MAIL ADDRESS:**
- **STREET 1:** C/O WINSTON & STRAWN LLP
- **STREET 2:** 800 CAPITOL ST., STE 2400
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77002

**VERAXA BIOTECH HOLDING AG**

Talacker 35

8001 Zurich, Switzerland

February 13, 2026

<u>VIA EDGAR</u>

Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

Re: Veraxa Biotech Holding AG (the "**Registrant**") Registration Statement on Form F-4 (File No. 333-289108) (the "**Registration Statement**")

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Registrant, Voyager Acquisition Corp. and Veraxa Biotech AG (each a "**Co-Registrant**"), respectfully request that the effective date of the Company's above-referenced Registration Statement be accelerated so that the same will become effective at 5:00 p.m. ET on February 17, 2026, or as soon thereafter as is practicable.

It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform Andrew M. Tucker of Duane Morris LLP, by telephone at (202) 776-5248 or by email at atucker@duanemorris.com or Michael J. Blankenship of Winston & Strawn LLP, by telephone at (713) 651-2600 or by email at mblankenship@winston.com. The Registrant and the Co-Registrants hereby authorize Mr. Tucker or Mr. Blankenship to orally modify or withdraw this request for acceleration.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| VERAXA BIOTECH HOLDING AG | VERAXA BIOTECH HOLDING AG |
| By: | /s/ Oliver Baumann |
| Name: | Oliver Baumann |
| Title: | General Manager |

---

---

| | |
|:---|:---|
| VOYAGER ACQUISITION CORP. | VOYAGER ACQUISITION CORP. |
| By: | /s/ Adeel Rouf |
| Name: | Adeel Rouf |
| Title: | Chief Executive Officer, President and Director |
| VERAXA BIOTECH AG | VERAXA BIOTECH AG |
| By: | /s/ Christoph Antz |
| Name: | Christoph Antz |
| Title: | Chief Executive Officer and Co-Founder |

---